SFCM
CTMX icon

Seven Fleet Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Seven Fleet Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07M Buy
1,085,398
+714,000
+192% +$2.73M 0.67% 28
2026
Q1 		$1.75M Buy
371,398
+322,500
+660% +$1.64M 0.55% 43
2025
Q4 		$208K Buy
+48,898
New +$186K 0.14% 64

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Seven Fleet Capital Management's CTMX Position: Q2 2026 in Review

Seven Fleet Capital Management increased its CytomX Therapeutics (CTMX) stake by 192% in Q2 2026, buying an estimated $2.73M and bringing the position to 1,085,398 shares worth $4.07M. The position accounts for 0.67% of the portfolio, ranked #28.

Seven Fleet Capital Management first reported a position in CTMX in Q4 2025 and has held it in 3 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Seven Fleet Capital Management held 1,085,398 shares of CytomX Therapeutics worth $4.07M as of Q2 2026.
  • Seven Fleet Capital Management bought 714,000 CytomX Therapeutics shares in Q2 2026, an estimated $2.73M.
  • CytomX Therapeutics made up 0.67% of Seven Fleet Capital Management's portfolio in Q2 2026, its #28 holding.
  • Seven Fleet Capital Management first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.